Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIFC NASDAQ:CNTX NASDAQ:CRDF NASDAQ:GTBP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.37-5.8%$0.63$0.36▼$9.76$54.86M1.75989,411 shs1.09 million shsCNTXContext Therapeutics$0.62+4.5%$1.16$0.55▼$3.62$54.26M1.752.54 million shs1.20 million shsCRDFCardiff Oncology$0.81-1.0%$1.31$0.76▼$3.31$56.03M1.441.68 million shs1.20 million shsGTBPGT Biopharma$0.30-4.0%$0.43$0.26▼$2.11$14.04M0.84801,275 shs662,789 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-5.76%-23.58%-37.34%-57.84%-93.87%CNTXContext Therapeutics+4.47%+0.59%+6.91%-73.86%-25.66%CRDFCardiff Oncology-0.98%-5.81%-36.22%-53.18%-75.53%GTBPGT Biopharma-4.01%-12.04%-30.91%-1.36%-85.10%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFCALT5 Sigma$0.37-5.8%$0.63$0.36▼$9.76$54.86M1.75989,411 shs1.09 million shsCNTXContext Therapeutics$0.62+4.5%$1.16$0.55▼$3.62$54.26M1.752.54 million shs1.20 million shsCRDFCardiff Oncology$0.81-1.0%$1.31$0.76▼$3.31$56.03M1.441.68 million shs1.20 million shsGTBPGT Biopharma$0.30-4.0%$0.43$0.26▼$2.11$14.04M0.84801,275 shs662,789 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFCALT5 Sigma-5.76%-23.58%-37.34%-57.84%-93.87%CNTXContext Therapeutics+4.47%+0.59%+6.91%-73.86%-25.66%CRDFCardiff Oncology-0.98%-5.81%-36.22%-53.18%-75.53%GTBPGT Biopharma-4.01%-12.04%-30.91%-1.36%-85.10%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFCALT5 Sigma 1.00SellN/AN/ACNTXContext Therapeutics 2.89Moderate Buy$6.17899.46% UpsideCRDFCardiff Oncology 2.17Hold$7.50825.93% UpsideGTBPGT Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest GTBP, CRDF, AIFC, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026CRDFCardiff Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/17/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/14/2026AIFCALT5 Sigma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/8/2026GTBPGT Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/16/2026CNTXContext Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $4.006/3/2026CRDFCardiff Oncology Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$2.006/1/2026CRDFCardiff Oncology TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold6/1/2026CRDFCardiff Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/18/2026CRDFCardiff Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFCALT5 Sigma$24.84M2.08N/AN/A$9.07 per share0.04CNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/ACRDFCardiff Oncology$590K94.04N/AN/A$0.67 per share1.21GTBPGT BiopharmaN/AN/A$0.01 per share21.17$0.23 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFCALT5 Sigma-$344.51MN/AN/AN/AN/A-2,483.94%-68.25%-62.43%N/ACNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)CRDFCardiff Oncology-$45.85M-$0.67N/AN/AN/A-8,527.43%-95.51%-71.47%8/4/2026 (Estimated)GTBPGT Biopharma-$28.35M-$6.33N/AN/AN/AN/AN/A-102.03%8/13/2026 (Estimated)Latest GTBP, CRDF, AIFC, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026GTBPGT Biopharma-$0.08N/AN/AN/AN/AN/A8/5/2026Q2 2026CNTXContext Therapeutics-$0.10N/AN/AN/AN/AN/A8/4/2026Q2 2026CRDFCardiff Oncology-$0.17N/AN/AN/A$0.06 millionN/A5/18/2026Q1 2026AIFCALT5 SigmaN/A-$2.14N/A-$2.14N/A$4.71 million5/15/2026Q1 2026GTBPGT Biopharma-$0.08-$0.11-$0.03-$0.11N/AN/A5/14/2026Q1 2026CRDFCardiff Oncology-$0.13-$0.18-$0.05-$0.18$0.09 million$0.04 million5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAIFCALT5 SigmaN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AGTBPGT BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFCALT5 Sigma0.030.820.82CNTXContext TherapeuticsN/A8.968.96CRDFCardiff OncologyN/A3.273.27GTBPGT BiopharmaN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFCALT5 Sigma6.27%CNTXContext Therapeutics14.03%CRDFCardiff Oncology16.29%GTBPGT Biopharma8.15%Insider OwnershipCompanyInsider OwnershipAIFCALT5 Sigma0.21%CNTXContext Therapeutics4.80%CRDFCardiff Oncology8.50%GTBPGT Biopharma1.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIFCALT5 Sigma170139.84 million139.54 millionN/ACNTXContext Therapeutics791.88 million87.47 millionNot OptionableCRDFCardiff Oncology2068.50 million62.68 millionOptionableGTBPGT Biopharma844.34 million43.82 millionNo DataGTBP, CRDF, AIFC, and CNTX HeadlinesRecent News About These CompaniesA Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting DrugsJuly 6, 2026 | tmcnet.comA Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsJuly 1, 2026 | theglobeandmail.comA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyJune 23, 2026 | theglobeandmail.comAfter CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellJune 12, 2026 | financialpost.comFThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetJune 8, 2026 | markets.businessinsider.comThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma’s TriKE BetJune 8, 2026 | financialpost.comFGT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological InitiativesJune 1, 2026 | globenewswire.comEXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology RolloutJune 1, 2026 | finance.yahoo.comGT Biopharma Inc GTBPMay 20, 2026 | morningstar.comMThree TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesMay 19, 2026 | newswire.caGT Biopharma Reports First Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comA Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in OncologyMay 14, 2026 | markets.businessinsider.com"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesMay 14, 2026 | markets.businessinsider.comFirst Patient Dosed in Phase 1 Trial Marks Expansion of NK Cell Engager Platform Into Solid TumorsMay 14, 2026 | baystreet.ca‘Cold’ Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesMay 14, 2026 | financialpost.comFGT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid TumorsMay 14, 2026 | globenewswire.comEXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer TypesMay 14, 2026 | benzinga.comGT Biopharma Advances GTB-5550 via University Trial PactApril 7, 2026 | tipranks.comGT Biopharma (GTBP) Upgraded to Buy: Here's What You Should KnowMarch 16, 2026 | zacks.comGT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?March 12, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTBP, CRDF, AIFC, and CNTX Company DescriptionsALT5 Sigma NASDAQ:AIFC$0.37 -0.02 (-5.76%) As of 07/29/2026 04:00 PM EasternALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Context Therapeutics NASDAQ:CNTX$0.62 +0.03 (+4.47%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$0.61 0.00 (-0.65%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Cardiff Oncology NASDAQ:CRDF$0.81 -0.01 (-0.98%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$0.80 -0.01 (-1.23%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.GT Biopharma NASDAQ:GTBP$0.30 -0.01 (-4.01%) Closing price 07/29/2026 03:59 PM EasternExtended Trading$0.30 0.00 (-0.99%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
